There is no strong clinical support that they permanently increase girth, and improper technique can cause bruising, pain, scar tissue, nerve injury, or erectile dysfunction
What to Watch in the Second Half of 2026 With TRIUMPH-1, TRANSCEND-T2D-1, and the TRIUMPH-1 OSA substudy all now confirmed, the remaining milestones in 2026 are TRIUMPH-2 and TRIUMPH-3 and the NDA submission that follows them
No reconstitution concentration affects per-draw volume but not total peptide
Tirzepatide is available at your pharmacy
Increasing clinical research and emerging approvals for GLP-1 therapies in younger populations are enabling safer and more effective treatment options for adolescents
This expansion might ignite additional competitive pricing and improved access as insurers react to heat from patients and employers alike